Fluidigm Corporation (NASDAQ:FLDM) insider Levin Capital Strategies, L.P. purchased 144,200 shares of the firm’s stock in a transaction that occurred on Tuesday, October 17th. The stock was bought at an average cost of $4.59 per share, for a total transaction of $661,878.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Levin Capital Strategies, L.P. also recently made the following trade(s):

  • On Monday, October 9th, Levin Capital Strategies, L.P. purchased 50,000 shares of Fluidigm Corporation stock. The stock was bought at an average cost of $4.59 per share, for a total transaction of $229,500.00.
  • On Tuesday, October 10th, Levin Capital Strategies, L.P. purchased 95,843 shares of Fluidigm Corporation stock. The stock was bought at an average cost of $4.57 per share, for a total transaction of $438,002.51.
  • On Tuesday, September 12th, Levin Capital Strategies, L.P. purchased 60,000 shares of Fluidigm Corporation stock. The stock was bought at an average cost of $5.25 per share, for a total transaction of $315,000.00.
  • On Thursday, August 17th, Levin Capital Strategies, L.P. purchased 465 shares of Fluidigm Corporation stock. The stock was bought at an average cost of $3.66 per share, for a total transaction of $1,701.90.
  • On Thursday, August 10th, Levin Capital Strategies, L.P. acquired 4,003,129 shares of Fluidigm Corporation stock. The stock was acquired at an average price of $3.30 per share, with a total value of $13,210,325.70.
  • On Wednesday, August 9th, Levin Capital Strategies, L.P. acquired 1,549 shares of Fluidigm Corporation stock. The stock was acquired at an average price of $3.18 per share, with a total value of $4,925.82.

Fluidigm Corporation (NASDAQ:FLDM) traded up 7.16% during mid-day trading on Monday, reaching $5.39. 284,300 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $4.98 and its 200 day moving average is $4.50. The stock’s market capitalization is $158.54 million. Fluidigm Corporation has a 1-year low of $2.52 and a 1-year high of $8.69.

Fluidigm Corporation (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.02. The firm had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.50 million. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The firm’s revenue was down 15.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.63) earnings per share. Analysts forecast that Fluidigm Corporation will post ($1.95) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Levin Capital Strategies, L.P. Buys 144,200 Shares of Fluidigm Corporation (FLDM) Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/23/levin-capital-strategies-l-p-buys-144200-shares-of-fluidigm-corporation-fldm-stock.html.

Hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its holdings in Fluidigm Corporation by 7.1% during the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock worth $102,000 after buying an additional 1,187 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in Fluidigm Corporation during the second quarter worth about $105,000. PDT Partners LLC boosted its holdings in Fluidigm Corporation by 56.0% during the second quarter. PDT Partners LLC now owns 27,300 shares of the medical research company’s stock worth $110,000 after buying an additional 9,800 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock valued at $146,000 after purchasing an additional 3,327 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Fluidigm Corporation by 18.4% in the second quarter. Alliancebernstein L.P. now owns 45,700 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 7,100 shares in the last quarter. 88.85% of the stock is currently owned by hedge funds and other institutional investors.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.